Superficial bacterial skin infection (S. aureus or S. pyogenes) producing honey-colored crusted erosions; highly contagious in children.
Also known as: impetigo, non-bullous impetigo, bullous impetigo, ecthyma
Overview
Highly contagious superficial bacterial skin infection caused predominantly by Staphylococcus aureus and Streptococcus pyogenes. Classified as non-bullous (most common), bullous, or ecthyma (ulcerative deeper variant).
Epidemiology
Most common bacterial skin infection in children ages 2-5; peak incidence in summer/fall. Affects ~140 million people globally. Bullous impetigo predominantly in neonates and young children. Higher rates in crowded conditions, hot/humid climates, and individuals with atopic dermatitis.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Impetigo outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Non-bullous impetigo: bacteria invade skin through breaks in barrier, producing intraepidermal pustules that rupture and crust. Bullous impetigo: S. aureus phage group II produces exfoliative toxin (ET-A) that cleaves desmoglein-1 in the granular layer → flaccid bullae. Ecthyma: deeper dermal invasion → ulcerative crusted lesion that heals with scar.
Non-bullous: thin-walled vesicle/pustule on erythematous base → rapidly ruptures → erosion with honey-colored (yellow-brown) crust; face (perioral, perinasal), extremities; well-demarcated; minimal surrounding inflammation
Bullous: flaccid clear/cloudy bullae 1-5 cm on intact skin (no erythematous base required) that rupture leaving collarette of scale and varnish-like brown crust; trunk, extremities, intertriginous areas; neonates and young children
Ecthyma: punched-out ulcer with adherent yellow-gray crust and surrounding violaceous halo; lower extremities; heals with scarring
Regional lymphadenopathy in 90% of non-bullous cases
Classic findings
Honey-colored crust on superficial erosions in a child; flaccid bullae with brown varnish-like crusts (bullous form).
Differential diagnosis
Herpes simplex (HSV) — Grouped vesicles on erythematous base, prodromal tingling, recurrent in same site; Tzanck/PCR positive
Varicella — Generalized eruption in different stages, fever, vesicles on erythematous base ('dew drop on rose petal')
Contact dermatitis with secondary infection — Pattern matches exposure; pruritus predominant before crusting
Tinea corporis with secondary infection — Annular plaque with peripheral scale; KOH positive
Staphylococcal scalded skin syndrome (SSSS) — Diffuse erythema and superficial desquamation; positive Nikolsky; fever; young child
Ecthyma gangrenosum (vs ecthyma) — Necrotic ulcer with black eschar in neutropenic patient; Pseudomonas bacteremia
Diagnostic workup
Diagnostic criteria
Clinical: characteristic honey-colored crusted lesions or flaccid bullae in a typical patient; culture confirms organism and susceptibility.
Labs
Clinical diagnosis usually sufficient
Gram stain and culture of exudate (especially in suspected MRSA, treatment failure, severe disease, outbreaks)
Anti-DNase B and anti-streptolysin O titers (rising in post-streptococcal glomerulonephritis surveillance — not routine)
Urinalysis 1-3 weeks after streptococcal impetigo if PSGN suspected (hematuria, edema, HTN)
Imaging
Not indicated
Diagnostic algorithm
Variant
Hallmark
Therapy
Non-bullous
Honey-colored crusts on face/extremities
Topical mupirocin × 5 d (limited); oral cephalexin/dicloxacillin × 7 d (extensive)
Bullous
Flaccid bullae → varnish-like brown crust (toxin-mediated)
Oral cephalexin/dicloxacillin; admit neonates
Ecthyma
Punched-out ulcer with adherent crust, scars on healing
Oral antibiotics × 7-10 d; local wound care
MRSA-suspected
Treatment failure, purulent, abscess
Clindamycin, TMP-SMX, or doxycycline based on susceptibilities
Impetigo variants and antimicrobial selection.
Treatment
First-line
Limited (≤5 lesions, small body area, non-bullous): topical mupirocin 2% ointment TID × 5 days OR topical retapamulin 1% ointment BID × 5 days OR topical ozenoxacin 1% cream BID × 5 days
Extensive, bullous, ecthyma, or treatment failure (systemic antibiotics × 7 days): cephalexin 25-50 mg/kg/day divided QID (pediatric) or 250-500 mg QID (adult); dicloxacillin 12.5 mg/kg/day pediatric or 250-500 mg QID adult — covers MSSA and S. pyogenes
Penicillin-allergic (non-anaphylactic): cephalexin acceptable; (anaphylactic): clindamycin 10-30 mg/kg/day pediatric or 300-450 mg QID adult, or doxycycline (≥8 years)
MRSA suspected: clindamycin (check D-test for inducible resistance), trimethoprim-sulfamethoxazole, doxycycline, linezolid; mupirocin remains effective for many MRSA strains
Hygiene: hand washing, nail trimming, separate towels and bedding, cover lesions; school exclusion until 24 hours of antibiotics or lesions crusted over
Decolonization for recurrent: intranasal mupirocin BID × 5 days + chlorhexidine washes + household decontamination
Bullous impetigo (neonates)
Low threshold for hospital admission, IV antibiotics (nafcillin, oxacillin, vancomycin if MRSA risk)
Differentiate from staphylococcal scalded skin syndrome which requires broader management
Ecthyma
Systemic antibiotics (as above) × 7-10 days
Local wound care with gentle debridement
Counsel: heals with scarring (unlike standard impetigo)
Second-line / adjunct
Mupirocin resistance documented in some regions — fusidic acid or retapamulin are alternatives
Bleach baths for recurrent disease in atopic dermatitis patients
Treat underlying skin disease (scabies, eczema)
Complications
Cellulitis, lymphangitis, bacteremia
Post-streptococcal glomerulonephritis (PSGN) — 1-5% incidence after streptococcal skin infection, 1-3 weeks post-infection; antibiotic treatment does NOT prevent PSGN once infection established
Acute rheumatic fever is NOT a complication of streptococcal impetigo (unlike pharyngitis)
Staphylococcal scalded skin syndrome (SSSS) from toxin spread
Scarlet fever
Permanent scarring from ecthyma
Recurrence with persistent nasal/skin S. aureus colonization
PANCE pearls
Honey-colored crust on a child's face = impetigo. Topical mupirocin × 5 days is sufficient for limited disease.
Bullous impetigo is caused by S. aureus exfoliative toxin (same family that produces SSSS); the bullae are typically on intact-appearing skin without erythematous halo.
Antibiotic treatment of streptococcal impetigo does NOT prevent post-streptococcal glomerulonephritis once infection is established — but does prevent transmission and other complications.
Recurrent impetigo warrants S. aureus decolonization (intranasal mupirocin + chlorhexidine).
Ecthyma heals with scarring; standard impetigo does not.
References
IDSA 2014 — Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America (Stevens et al., Clin Infect Dis 2014)
AAP Red Book 2024 — American Academy of Pediatrics Red Book — Staphylococcal and Streptococcal Skin Infections (2024 update)
AAFP 2014 — Impetigo: Diagnosis and Treatment (Hartman-Adams, Banvard, Juckett, Am Fam Physician 2014)
Practice Dermatology questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.